About Us
Emersed in an ecosystem of pharma and technology companies, MHG takes an Orchestrated approach to drug development with a time to value focus.
We embrace multi-disciplinary teams, repurposing and partnerships and Web 3 for accelerated outcomes.
Our team of practitioners have combined 200+ years of experience in drug development, pharma distribution, AI & data science, M&A.
We have relationships with leading hospitals and research institutions who partner with us for clinical studies and drug development.
What we Do?
Releasing Trapped Value in Intellectual Property
Small Molecules are the building blocks for drugs.
Friction getting to market is very high often resulting in trapped value - science (drugs / therapies) that does not ever reach the patient.
MHG is focused on accelerating the time to market for new drugs which could be enhancing longevity, treating diseases for children, treating neurological diseases like Parkinson's and multiple sclerosis, and addressing unmet needs in orphan diseases.
Our business model focuses on a niche space whereby drugs can be brought to market with accelerated and derisked pathways. Repurposing (Drpx), CRO outsourcing & decentralized trials, low-cost region operations.
We orchestrate the connection between inventors & investors.
We bring together: IP + Teams + Clinical pathways + Investment Vehicles.
Result = Value to Patents
Return to Inventor + Return to Investor + Return to Collaborators
How we do it
Overall Approach:
We apply our multi-disciplinary team in identifying the Value potential of small molecule IP and how to release that value through orchestrated mobilization into Special Purpose Vehicles.
Our practitioner led team affords us ability to assess IP value, risk reduced clinical pathways to market and design governance structures that are compelling for investors. We have low overhead and success-based incentives as integral to compensation structures for all involved. Time to value is our focus.
We collaborate with CROs and university research groups in win-win partnership models. By doing so we leverage the best talent and reduce the overall risks of development.
Exciting New Opportunity
Change is occurring today in approach to fund raising (DEFI) & governance (tokenization & blockchain) - our team is ready to embrace.
The emergence of decentralized science (DESCCI) is offering unique access to financing (DEFI) and capability to orchestrate the participation of many collaborators in the drug development process. Our term has multi-disciplinary experience in Business Transformation + Clinical Project Mgmt + Healthcare systems + blockchain + AI + drug design + distribution.